India’s Saptagir Partners With Jubilant On Remdesivir
As Dr Reddy’s Launches Its Version Through Gilead Partnership
Executive Summary
India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.
You may also be interested in...
Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Hikma Is Keeping On Top Of COVID ‘Rollercoaster’
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.
How Cipla Is Aligning Manufacturing Amid The Pandemic
Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.